跳至主要内容
临床试验/NCT02527616
NCT02527616已完成不适用

A Randomised, Crossover Investigation to Evaluate and Compare the Effectiveness, Safety and Feasibility of a Novel Dedicated Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for Measuring Fractional Flow Reserve (FFR) Using Intra-coronary Non-weight Adjusted Adenosine Infusion With the Standard Intra-venous Administration of Adenosine, in Subjects With Intermediate Coronary Artery Stenosis.

Diasolve Ltd2 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2016年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
41
试验地点
2
主要终点
Number of participants with comparable FFR ratio recordings

研究概览

简要总结

This is a single-blinded, randomised, crossover investigation comparing the investigational device using intra-coronary (IC) Adenosine infusion to the standard intra-venous (IV) infusion method used for obtaining FFR measurements. All subjects requiring on a clinical basis a pressure wire assessment of intermediate coronary artery stenosis(es) will be eligible to take part in the investigation.

详细描述

Coronary artery disease is the most common type of heart disease that affects millions of people worldwide. It is caused by a narrowing or blocking of the arteries (known as stenosis) due to plaque, which restricts blood flow and reduces the amount of oxygen to the heart.

Over the past decade, fractional flow reserve (FFR) measurement has been increasingly used in cardiac catheterization laboratories, providing a straightforward and readily available quantitative assessment of the functional severity of a coronary artery stenosis, as the ability of the cardiologist to discriminate between stenoses that can cause ischemia and those that are physiologically insignificant on the basis of coronary angiography alone is limited.

Measuring FFR determines the ratio between the maximum achievable blood flow in a diseased or narrowed coronary artery and the maximum blood flow in a normal coronary artery. This ratio represents the potential decrease in coronary flow distal to the coronary stenosis.

FFR is easily measured during routine coronary angiography by using a pressure wire to calculate the ratio between the coronary pressure distal to a stenosis or a diseased segment and the aortic pressure under conditions of maximum myocardial hyperemia. An FFR of 1.0 is widely accepted as normal. An FFR lower than 0.80 is generally considered to be associated with coronary ischemia and widely accepted in favour of revascularization over conservative management.

The current standard methods of measuring FFR is to insert a pressure wire into the coronary artery while the hyperaemic agent, normally adenosine, is delivered by continuous intravenous infusion via a central femoral vein, a large ante-cubital peripheral cannula or intra-coronary bolus injection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Diagnostic
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability and willingness to give written informed consent prior to investigation participation.
  • Has given consent to undergo hospital's diagnostic or interventional coronary procedure.
  • Male and female subjects aged 18 and over.
  • Ability to communicate well with the investigator and to comply with the requirements of the clinical investigation.
  • Prior to randomisation:
  • Coronary angiogram demonstrates at least one coronary stenosis of intermediate severity (40-70%), in a non-infarct related artery, which requires FFR measurement for physiological assessment.

排除标准

  • Known sensitivity to adenosine or any of its excipients
  • Technically inaccessible stenosis(es)
  • Acute ST segment elevation myocardial infarction (STEMI)
  • Haemodynamically unstable
  • Presence of any clinically significant medical condition as determined by the investigator
  • Participation in another clinical investigation within the three months prior.

结局指标

主要结局

Number of participants with comparable FFR ratio recordings

时间窗: Intraoperative

The FFR ratio should remain constant when measured by the standard method and the investigational device.

次要结局

  • Dose of adenosine administered.(Intraoperative)
  • Number of participants with Adverse Events(Intraoperative)
  • Time to onset of maximum hyperaemia.(Intraoperative)

研究者

发起方
Diasolve Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验